Literature DB >> 11058605

Human Nod1 confers responsiveness to bacterial lipopolysaccharides.

N Inohara1, Y Ogura, F F Chen, A Muto, G Nuñez.   

Abstract

The immune response to microbial pathogens is initiated by recognition of specific pathogen components by host cells both at the cell surface and in the cytosol. While the response triggered by pathogen products at the surface of immune cells is well characterized, that initiated in the cytosol is poorly understood. Nod1 is a member of a growing family of intracellular proteins with structural homology to apoptosis regulators Apaf-1/Ced-4 and a class of plant disease-resistant gene products. Here we show that bacterial lipopolysaccharides, but not other pathogen components tested, induced TLR4- and MyD88-independent NF-kappaB activation in human embryonic kidney 293T cells expressing trace amounts of Nod1. Nod2, another Nod family member, also conferred responsiveness to bacterial components but with a response pattern different from that observed with Nod1. As it was reported for plant disease-resistant R proteins, the leucine-rich repeats of Nod1 and Nod2 were required for lipopolysaccharide-induced NF-kappaB activation. A lipopolysaccharide binding activity could be specifically coimmunopurified with Nod1 from cytosolic extracts. These observations suggest that Nod1 and Nod2 are mammalian counterparts of plant disease-resistant gene products that may function as cytosolic receptors for pathogen components derived from invading bacteria.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11058605     DOI: 10.1074/jbc.M009728200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  127 in total

1.  Two distinct domains within CIITA mediate self-association: involvement of the GTP-binding and leucine-rich repeat domains.

Authors:  M W Linhoff; J A Harton; D E Cressman; B K Martin; J P Ting
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

Review 2.  Clinical aspects and pathophysiology of inflammatory bowel disease.

Authors:  Barbara A Hendrickson; Ranjana Gokhale; Judy H Cho
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

Review 3.  The biology of endotoxin.

Authors:  H Heine; E T Rietschel; A J Ulmer
Journal:  Mol Biotechnol       Date:  2001-11       Impact factor: 2.695

Review 4.  Activation of the immune system by bacterial CpG-DNA.

Authors:  Georg Häcker; Vanessa Redecke; Hans Häcker
Journal:  Immunology       Date:  2002-03       Impact factor: 7.397

Review 5.  Toll receptors: a central element in innate immune responses.

Authors:  Thierry Vasselon; Patricia A Detmers
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

6.  CARD4/NOD1 is not involved in inflammatory bowel disease.

Authors:  H Zouali; S Lesage; F Merlin; J-P Cézard; J-F Colombel; J Belaiche; S Almer; C Tysk; C O'Morain; M Gassull; S Christensen; Y Finkel; R Modigliani; C Gower-Rousseau; J Macry; M Chamaillard; G Thomas; J-P Hugot
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

7.  Card15 gene overexpression in mononuclear and epithelial cells of the inflamed Crohn's disease colon.

Authors:  D Berrebi; R Maudinas; J-P Hugot; M Chamaillard; F Chareyre; P De Lagausie; C Yang; P Desreumaux; M Giovannini; J-P Cézard; H Zouali; D Emilie; M Peuchmaur
Journal:  Gut       Date:  2003-06       Impact factor: 23.059

8.  Innate recognition of bacteria by a macrophage cytosolic surveillance pathway.

Authors:  Mary O'Riordan; Caroline H Yi; Ramona Gonzales; Kyung-Dall Lee; Daniel A Portnoy
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-01       Impact factor: 11.205

Review 9.  CARD games in apoptosis and immunity.

Authors:  Lisa Bouchier-Hayes; Seamus J Martin
Journal:  EMBO Rep       Date:  2002-07       Impact factor: 8.807

Review 10.  The potential for Toll-like receptors to collaborate with other innate immune receptors.

Authors:  Subhankar Mukhopadhyay; Jurgen Herre; Gordon D Brown; Siamon Gordon
Journal:  Immunology       Date:  2004-08       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.